BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
